The impact of timing and duration of thiopurine treatment on first intestinal resection in crohn's disease: National UK population-based study 1989-2010

American Journal of Gastroenterology

Volumn 109, Issue 3, 2014, Pages 409-416

  Chatu, Sukhdev ^a   Saxena, Sonia ^b   Subramanian, Venkataraman ^c   Curcin, Vasa ^b   Yadegarfar, Ghasem ^b   Gunn, Laura ^b,d   Majeed, Azeem ^b   Pollok, Richard C G ^a  

^a ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^d STETSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MERCAPTOPURINE;

ADULT; ARTICLE; CROHN DISEASE; FEMALE; HUMAN; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK FACTOR; TREATMENT DURATION; UNITED KINGDOM; YOUNG ADULT;

6-MERCAPTOPURINE; ADULT; AZATHIOPRINE; CROHN DISEASE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; FOLLOW-UP STUDIES; GREAT BRITAIN; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROPENSITY SCORE; PROSPECTIVE STUDIES; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME;

EID: 84895808238     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2013.462     Document Type: Article

References (44)

1. Prefontaine E, Sutherland LR, MacDonald JK et al. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; 9: CD000067.
2. Cosnes J, Cattan S, Blain A et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002; 8: 244-50.
3. Louis E, Collard A, Oger AF et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut 2001; 49: 777-82.
4. Loftus EV Jr. Crohn's disease: why the disparity in mortality? Gut 2006; 55: 447-9.
5. Gollop JH, Phillips SF, Melton LJ III et al. Epidemiologic aspects of Crohn's disease: a population based study in Olmsted County, Minnesota, 1943-1982. Gut 1988; 29: 49-56.
6. Munkholm P, Langholz E, Davidsen M et al. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706.
7. Solberg IC, Vatn MH, Hoie O et al. Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol 2007; 5: 1430-8.
8. Solberg IC, Lygren I, Jahnsen J et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol 2009; 44: 431-40.
9. Wolters FL, Russel MG, Sijbrandij J et al. Phenotype at diagnosis predicts recurrence rates in Crohn's disease. Gut 2006; 55: 1124-30.
10. Cosnes J, Nion-Larmurier I, Beaugerie ie L et al. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-41.
11. Ramadas AV, Gunesh S, Th omas GAO et al. Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010; 59: 1200-6.
12. Vernier-Massouille G, Balde M, Salleron J et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008; 135: 1106-13.
13. Knevel R, Schoels M, Huizinga TW et al. Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2010; 69: 987-94.
14. Herrett E, Th omas SL, Schoonen WM et al. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69: 4-14.
15. Khan NF, Harrison SE, Rose PW. Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 2010; 60: e128-36.
16. Chen YC, Wu JC, Haschler I et al. Academic impact of a public electronic health database: bibliometric analysis of studies using the General Practice Research Database. PLoS ONE 2011; 6: e21404.
17. Lewis JD, Brensinger C, Bilker WB et al. Validity and completeness of the General Practice Research Database for studies of inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2002; 11: 211-8.
18. Lewis JD, Aberra FN, Lichtenstein GR et al. Seasonal variation in flares of inflammatory bowel disease. Gastroenterology 2004; 126: 665-73.
19. Cosnes J, Beaugerie L, Carbonnel F et al. Smoking cessation and the course of Crohn's disease: an intervention study. Gastroenterology 2001; 120: 1093-9.
20. Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 2004; 18: 481-96.
21. Cosnes J, Seksik P, Nion-Larmurier I et al. Prior appendectomy and the phenotype and course of Crohn's disease. World J Gastroenterol 2006; 12: 1235-42.
22. Lakatos PL, Golovics PA, David G et al. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from western Hungary between 1977-2009. Am J Gastroenterol 2012; 107: 579-88.
23. Nguyen GC, Tuskey A, Dassopoulos T et al. Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis 2007; 13: 1529-35.
24. Schaefer ME, Machan JT, Kawatu D et al. Factors that determine risk for surgery in pediatric patients with Crohn's disease. Clin Gastroenterol Hepatol 2010; 8: 789-94.
25. Cosnes J, Bourrier A, Laharie D et al. Early administration of azathioprine vs. conventional management of Crohn's disease: a randomized controlled trial. Gastroenterology 2013; 145: 758-765.e2.
26. Panes J, Lopez-Sanroman A, Bermejo F et al. Early azathioprine therapy is no more Effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013; 145: 766-774.e1.
27. Picco MF, Zubiaurre I, Adluni M et al. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating nonstricturing Crohn's disease. Am J Gastroenterol 2009; 104: 2754-9.
28. Peyrin-Biroulet L, Oussalah A, Williet N et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease. Gut 2011; 60: 930-6.
29. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231: 38-45.
30. Gupta N, Cohen SA, Bostrom AG et al. Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology 2006; 130: 1069-77.
31. Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's Disease. Cochrane Database Syst Rev 2005;(1): CD003715.
32. Lindberg E, Jarnerot G, Huitfeldt B. Smoking in Crohn's disease: Effect on localisation and clinical course. Gut 1992; 33: 779-82.
33. Morimoto N, Kato J, Kuriyama M et al. Risk factors and indications for first surgery in Crohn's disease patients. Hepatogastroenterology 2007; 54: 2011-6.
34. Majeed A, Molokhia M. Primary care in the United kingdom. J Ambul Care Manage 2008; 31: 198-200.
35. Majeed A. Sources, uses, strengths and limitations of data collected in primary care in England. Health Stat Q 2004;21: 5-14.
36. Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol 2007; 5: 597-601.
37. Jones DW, Finlayson SR. Trends in surgery for Crohn's disease in the era of infliximab. Ann Surg 2010; 252: 307-12.
38. Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn's disease. Dis Colon Rectum 2002; 45: 771-5.
39. NICE technology appraisal guidance 187 www.nice.org.uk/guidance/TA187.
40. Bardhan KD, Simmonds N, Royston C et al. A United Kingdom inflammatory bowel disease database: making the eff ort worthwhile. J Crohns Colitis 2010; 4: 405-12.
41. Lee JC, Lyons PA, McKinney EF et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. J Clin Invest 2011; 121: 4170-9.
42. Chouchana L, Narjoz C, Beaune P et al. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Th er 2012; 35: 15-36.
43. Hoentjen F, Seinen ML, Hanauer SB et al. Safety and Effectiveness of longterm allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 363-9.
44. Smith M, Blaker P, Patel C et al. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Int J Clin Pract 2013; 67: 161-9.